Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors
€5 million convertible bonds issued to European investors,
European investors have also provided written indication of strong interest for the potential of additional €25 million in similar convertible bonds, depending on future market conditions
PARIS, FRANCE / ACCESSWIRE / February 4, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the
Company ), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, today announced a financing of €11 million through the combination of a €6 million capital raise subscribed by two existing shareholders by way of issuance of new ordinary shares (the